14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
As of Jul 31, 2026, PLUS THERAPEUTICS, Inc. (PSTV) is the stronger overall head-to-head candidate over Keen Vision Acquisition Corporation (KVAC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow). KVAC carries a Unified Composite Score of 58.0/100 (HOLD) at $11.51 (N/M Forward P/E, 0.0% operating margin), whereas PSTV carries 59.8/100 (HOLD) at $3.87 (1.0x Forward P/E, -692.5% operating margin).
Technical & Structure Timing Caution: KVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile PSTV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KVAC vs PSTV. Trailing 12-month operating profitability (KVAC 0.0% vs PSTV -692.5%) and valuation multiples (KVAC N/M vs PSTV 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $25.1M market capitalization and -692.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KVAC vs PSTV Key Questions & Quantitative Answers
As of Jul 31, 2026, PLUS THERAPEUTICS, Inc. (PSTV) is the stronger overall head-to-head candidate over Keen Vision Acquisition Corporation (KVAC) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow). KVAC carries a Unified Composite Score of 58.0/100 (HOLD) at $11.51 (N/M Forward P/E, 0.0% operating margin), whereas PSTV carries 59.8/100 (HOLD) at $3.87 (1.0x Forward P/E, -692.5% operating margin). Technical & Structure Timing Caution: KVAC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile PSTV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KVAC leads the Growth & Scale pillar: KVAC posts +0.0% YoY revenue growth and -76.9% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PSTV at -2.9% YoY revenue growth and +0.0% YoY earnings growth on $5.2M TTM revenue (-83.1% gross margin, -692.5% operating margin). On trailing 12-month operating scale, KVAC generates N/A in USD-normalized revenue versus $5.2M for PSTV. In operating R&D and SG&A reinvestment, KVAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PSTV.
PSTV screens cheaper on headline valuation multiples. KVAC trades at N/M Forward P/E, 88.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PSTV trades at 1.0x Forward P/E, 0.2x Trailing P/E, 2.45x PEG, and 4.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KVAC (0.0% ROE) versus PSTV (-522.5% ROE) capital efficiency.
In options market volatility and institutional positioning, KVAC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.17β · 76% Vol realized risk). By comparison, PSTV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.04β · 50% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jul 31, 2026. For educational research only; not investment advice.